Charles Schwab’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.2M | Sell |
1,401,476
-210,669
| -13% | -$2.95M | ﹤0.01% | 1698 |
|
|
2026
Q1 | $15.2M | Buy |
1,612,145
+52,191
| +3% | +$573K | ﹤0.01% | 1897 |
|
|
2025
Q4 | $19.4M | Buy |
1,559,954
+169,908
| +12% | +$2.26M | ﹤0.01% | 1769 |
|
|
2025
Q3 | $19.9M | Buy |
1,390,046
+169,043
| +14% | +$2.32M | ﹤0.01% | 1741 |
|
|
2025
Q2 | $15M | Buy |
1,221,003
+74,082
| +6% | +$1.08M | ﹤0.01% | 1819 |
|
|
2025
Q1 | $25.2M | Buy |
1,146,921
+99,348
| +9% | +$2.34M | ﹤0.01% | 1501 |
|
|
2024
Q4 | $23.8M | Buy |
1,047,573
+103,291
| +11% | +$2.25M | ﹤0.01% | 1607 |
|
|
2024
Q3 | $17.2M | Buy |
944,282
+125,620
| +15% | +$2.91M | ﹤0.01% | 1777 |
|
|
2024
Q2 | $23.9M | Buy |
818,662
+221,078
| +37% | +$6.56M | ﹤0.01% | 1560 |
|
|
2024
Q1 | $21.2M | Buy |
597,584
+33,983
| +6% | +$1.36M | ﹤0.01% | 1574 |
|
|
2023
Q4 | $24.5M | Buy |
563,601
+17,863
| +3% | +$703K | 0.01% | 1466 |
|
|
2023
Q3 | $20.8M | Sell |
545,738
-156,702
| -22% | -$6.59M | 0.01% | 1487 |
|
|
2023
Q2 | $28.9M | Sell |
702,440
-88,275
| -11% | -$4.25M | 0.01% | 1239 |
|
|
2023
Q1 | $45.4M | Buy |
790,715
+50,747
| +7% | +$2.86M | 0.01% | 909 |
|
|
2022
Q4 | $41.5M | Buy |
739,968
+71,125
| +11% | +$3.62M | 0.01% | 941 |
|
|
2022
Q3 | $28.3M | Buy |
668,843
+9,777
| +1% | +$501K | 0.01% | 1137 |
|
|
2022
Q2 | $35.6M | Buy |
659,066
+138
| +0% | +$8.29K | 0.01% | 981 |
|
|
2022
Q1 | $42.3M | Buy |
658,928
+23,751
| +4% | +$1.56M | 0.01% | 982 |
|
|
2021
Q4 | $42.6M | Buy |
635,177
+18,554
| +3% | +$1.26M | 0.01% | 1015 |
|
|
2021
Q3 | $42.2M | Buy |
616,623
+30,154
| +5% | +$2.13M | 0.01% | 994 |
|
|
2021
Q2 | $40M | Buy |
586,469
+19,848
| +4% | +$1.4M | 0.01% | 1032 |
|
|
2021
Q1 | $39.1M | Buy |
566,621
+14,317
| +3% | +$970K | 0.01% | 990 |
|
|
2020
Q4 | $35.9M | Sell |
552,304
-1,196
| -0.2% | -$64.4K | 0.01% | 992 |
|
|
2020
Q3 | $26.1M | Buy |
553,500
+119
| +0% | +$5.66K | 0.01% | 1033 |
|
|
2020
Q2 | $26M | Buy |
553,381
+33
| +0% | +$1.62K | 0.01% | 992 |
|
|
2020
Q1 | $24.7M | Buy |
553,348
+2,414
| +0.4% | +$127K | 0.01% | 871 |
|
|
2019
Q4 | $32.1M | Buy |
550,934
+6,704
| +1% | +$399K | 0.02% | 900 |
|
|
2019
Q3 | $32.7M | Buy |
544,230
+54,640
| +11% | +$3.26M | 0.02% | 847 |
|
|
2019
Q2 | $27.3M | Buy |
489,590
+13,192
| +3% | +$679K | 0.02% | 930 |
|
|
2019
Q1 | $26.5M | Buy |
476,398
+32,598
| +7% | +$1.66M | 0.02% | 933 |
|
|
2018
Q4 | $20M | Buy |
443,800
+1,023
| +0.2% | +$56.1K | 0.02% | 1003 |
|
|
2018
Q3 | $29.2M | Buy |
442,777
+139,546
| +46% | +$8.67M | 0.02% | 884 |
|
|
2018
Q2 | $19.5M | Sell |
303,231
-64,021
| -17% | -$3.96M | 0.01% | 1096 |
|
|
2018
Q1 | $20.3M | Buy |
367,252
+43,642
| +13% | +$2.29M | 0.02% | 988 |
|
|
2017
Q4 | $15.5M | Buy |
323,610
+29,836
| +10% | +$1.46M | 0.01% | 1172 |
|
|
2017
Q3 | $14.8M | Buy |
293,774
+24,218
| +9% | +$1.24M | 0.01% | 1136 |
|
|
2017
Q2 | $14.7M | Buy |
269,556
+24,574
| +10% | +$1.17M | 0.01% | 1080 |
|
|
2017
Q1 | $10.3M | Buy |
244,982
+19,008
| +8% | +$812K | 0.01% | 1293 |
|
|
2016
Q4 | $9.69M | Buy |
225,974
+14,770
| +7% | +$600K | 0.01% | 1277 |
|
|
2016
Q3 | $8.72M | Sell |
211,204
-83,886
| -28% | -$3.51M | 0.01% | 1266 |
|
|
2016
Q2 | $11.8M | Sell |
295,090
-21,184
| -7% | -$762K | 0.01% | 966 |
|
|
2016
Q1 | $10.7M | Buy |
316,274
+7,268
| +2% | +$226K | 0.01% | 1008 |
|
|
2015
Q4 | $10.5M | Sell |
309,006
-8,708
| -3% | -$272K | 0.01% | 988 |
|
|
2015
Q3 | $9.46M | Buy |
317,714
+56,759
| +22% | +$1.77M | 0.01% | 1036 |
|
|
2015
Q2 | $7.19M | Buy |
260,955
+9,387
| +4% | +$250K | 0.01% | 1288 |
|
|
2015
Q1 | $6.34M | Buy |
251,568
+14,671
| +6% | +$347K | 0.01% | 1342 |
|
|
2014
Q4 | $5.25M | Buy |
236,897
+6,652
| +3% | +$135K | 0.01% | 1407 |
|
|
2014
Q3 | $4.67M | Buy |
230,245
+35,161
| +18% | +$700K | 0.01% | 1412 |
|
|
2014
Q2 | $3.75M | Buy |
195,084
+12,147
| +7% | +$226K | 0.01% | 1605 |
|
|
2014
Q1 | $3.44M | Buy |
182,937
+9,487
| +5% | +$183K | 0.01% | 1617 |
|
|
2013
Q4 | $3.38M | Buy |
173,450
+28,357
| +20% | +$520K | 0.01% | 1567 |
|
|
2013
Q3 | $2.43M | Sell |
145,093
-7,254
| -5% | -$116K | 0.01% | 1731 |
|
|
2013
Q2 | $2.29M | Buy |
+152,347
| New | +$2.23M | 0.01% | 1679 |
|
Other funds holding IART
RCMNY
PCMI
Charles Schwab's IART Position: Q2 2026 in Review
Charles Schwab reduced its Integra LifeSciences (IART) stake by 13% in Q2 2026, selling an estimated $2.95M and leaving 1,401,476 shares worth $25.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1698.
Charles Schwab first reported a position in IART in Q2 2013 and has held it in 53 quarters since. The position peaked at $45.4M in Q1 2023. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- Charles Schwab held 1,401,476 shares of Integra LifeSciences worth $25.2M as of Q2 2026.
- Charles Schwab sold 210,669 Integra LifeSciences shares in Q2 2026, an estimated $2.95M.
- Integra LifeSciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1698 holding.
- Charles Schwab first reported a position in Integra LifeSciences in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Integra LifeSciences position peaked at $45.4M in Q1 2023.
- 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.